Subscribe
bill-oxford
Bill Oxford / IStockphoto.com
29 October 2018Americas

J&J reveals plans to appeal cancer drug court ruling

Johnson & Johnson (J&J) has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Big Pharma
Johnson & Johnson braces for Q3 sales dip as generics bite
18 July 2019   Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Big Pharma
Johnson & Johnson braces for Q3 sales dip as generics bite
18 July 2019   Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.

More on this story

Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Big Pharma
Johnson & Johnson braces for Q3 sales dip as generics bite
18 July 2019   Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.

More features

GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks
Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch